News
Trial results, approvals, pricing changes, safety findings and market moves across peptides and GLP-1 medications — each traced to a primary source, each dated. For enforcement actions specifically, see the regulatory tracker.
- Trial results
- Approvals
- Pricing changes
- Safety findings
-
Lilly reports one-year results for tirzepatide added to a psoriasis biologic
Read more: Lilly reports one-year results for tirzepatide added to a psoriasis biologicEli Lilly announced 52-week results on 31 August 2026 from two Phase 3b trials testing whether adding tirzepatide (Zepbound) to the psoriasis biologic ixekizumab (Taltz) works better than the biologic alone in adults who have psoriatic disease and obesity. It did, on both trials’ primary outcomes and by wide margins. But the primary outcomes were…
-
Weight comes back at about a kilogram a month after stopping, meta-analysis estimates
Read more: Weight comes back at about a kilogram a month after stopping, meta-analysis estimatesA meta-analysis published in Endocrinology, Diabetes & Metabolism in September 2026 puts a number on something patients ask about far more often than they are answered: what happens after you stop. Pooling six studies and 1,776 participants, it estimates weight comes back at 1.04 kg per month, that half of everything lost is back within…
-
Updated review of 38 trials ranks tirzepatide first among available drugs
Read more: Updated review of 38 trials ranks tirzepatide first among available drugsAn updated systematic review published in Annals of Internal Medicine on 1 September 2026 pooled 38 randomised trials covering 25,816 adults who had overweight or obesity but not diabetes. It is the cleanest single answer yet to the question most readers arrive with: how much weight does each of these drugs actually take off, above…
-
Hair loss on GLP-1s: 3% on the Wegovy label, 40% higher odds in pooled data
Read more: Hair loss on GLP-1s: 3% on the Wegovy label, 40% higher odds in pooled dataA new cohort study adds to a now-consistent finding: people taking semaglutide or tirzepatide are diagnosed with non-scarring hair loss more often than matched non-users. This is not a fringe signal — hair loss is printed on the Wegovy label, among the adverse reactions occurring in at least 2% of treated patients and more often…
-
Semaglutide patients lost 11 kg over a year and kept their grip strength
Read more: Semaglutide patients lost 11 kg over a year and kept their grip strengthA Barcelona hospital followed 83 adults with obesity through a year of routine care and measured what most weight-loss studies only estimate: fat, lean tissue, resting energy expenditure and handgrip strength. The 44 patients on semaglutide lost substantially more weight than the 39 on a lifestyle programme alone. They also lost lean tissue — about…
-
Wegovy’s 4 mg pill goes from $149 to $199 on 1 September
Read more: Wegovy’s 4 mg pill goes from $149 to $199 on 1 SeptemberThe self-pay price of the 4 mg Wegovy tablet rises from $149 to $199 a month on 1 September 2026. This is not a leak or a forecast: Novo Nordisk published the end date when it launched the offer, and the footnote was still on NovoCare’s own pricing page when we read it on 31…
-
A menopause society has issued guidance on GLP-1 use, and it is candid about the evidence gap
Read more: A menopause society has issued guidance on GLP-1 use, and it is candid about the evidence gapThe Spanish Menopause Society published an expert position statement on 25 August covering the use of GLP-1 and dual incretin medications in peri- and postmenopausal women with overweight or obesity. It sets out 20 positions across body composition, cardiometabolic risk, musculoskeletal health, monitoring and interaction with hormone therapy. The most useful thing in it, for…
-
Semaglutide cut inflammation as well as weight in a review of nine trials
Read more: Semaglutide cut inflammation as well as weight in a review of nine trialsA systematic review and meta-analysis published on 29 August pooled nine randomised trials covering 6,239 adults with overweight or obesity but without diabetes, and found that injected semaglutide reduced a standard marker of inflammation by roughly 40% alongside the weight loss it is prescribed for. Serious adverse events were no more common than on placebo.…
-
Online-bought retatrutide, a hospital admission, and the limits of a single case
Read more: Online-bought retatrutide, a hospital admission, and the limits of a single caseA case report published on 26 August describes a man in his mid-30s with long-standing type 1 diabetes who was admitted to hospital with severe vomiting, diarrhoea, high blood sugar, ketones and acute kidney injury, shortly after self-administering a product he had bought online marketed as retatrutide. His partner took the same preparation and also…
-
Retatrutide met its endpoints in two more Phase 3 trials, but not on cardiovascular events
Read more: Retatrutide met its endpoints in two more Phase 3 trials, but not on cardiovascular eventsEli Lilly reported on 23 July 2026 that retatrutide, an investigational triple hormone receptor agonist, met its primary endpoint in two further Phase 3 trials. Participants with obesity and type 2 diabetes lost up to an average of 20.8% of body weight over 80 weeks; those with severe obesity and established cardiovascular disease lost up…